This study is looking into psilocybin-assisted psychotherapy for people with advanced cancer who are also experiencing depression and/or anxiety. You might be able to join if you are 25 or older, have certain types of advanced cancer (like non-small cell lung cancer or breast cancer), and are currently receiving maintenance therapy. The study will give participants either psilocybin or niacin by mouth. Researchers want to see if this treatment is safe and how well it helps with depression and anxiety. They also want to understand if at least 20% of eligible people join and if at least 60% of those who join complete the two treatment doses. The study is currently unclear on its recruitment status and plans to enroll 30 participants.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It aims to enroll 30 participants, but the specific phase of the study is not mentioned.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Safety and side effects will be measured through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.